Inference Investigation

Claim investigated: To identify potential US regulatory footprints for Korean HPSP, researchers should investigate (1) CHIPS Act equipment procurement records, (2) Crescendo Equity Partners' US fund registrations, and (3) US semiconductor company supplier disclosures—not federal healthcare spending databases Entity: HPSP Original confidence: inferential Result: CONFIRMED → SECONDARY

Assessment

The inferential claim is technically correct but represents a complete methodological pivot after 40+ failed attempts to investigate the wrong entity. The claim accurately identifies that Korean HPSP's US regulatory footprint would appear through CHIPS Act procurement, Crescendo's SEC filings, or supplier disclosures—not healthcare databases—but this recommendation comes only after systematic research failure targeting an unrelated DoD program.

Reasoning: The claim's logic is sound and supported by regulatory frameworks: CHIPS Act procurement records would capture foreign equipment suppliers, SEC-registered funds must disclose portfolio holdings, and US semiconductor companies must disclose material supplier relationships. However, confidence remains secondary because the underlying Korean HPSP entity descriptions (639% return, 'world's only manufacturer') remain entirely unverified.

Underreported Angles

• The complete research methodology breakdown represents a case study in acronym disambiguation failure—40+ established facts addressed wrong entities despite clear identification of Korean semiconductor target
• Crescendo Equity Partners' 39.42% stake in Korean HPSP creates the most direct US regulatory touchpoint through mandatory SEC fund disclosure requirements
• CHIPS Act Section 9202 equipment procurement records could reveal foreign semiconductor equipment suppliers receiving indirect US federal funding
• The investigation's healthcare database focus while claiming to research semiconductor equipment manufacturer demonstrates systematic subject confusion that invalidated all findings

Public Records to Check

• SEC EDGAR: Crescendo Equity Partners AND (Form ADV OR Form 13F OR Schedule 13G) Would confirm the 39.42% HPSP stake and establish direct US regulatory disclosure pathway

• USASpending: CHIPS Act AND (semiconductor equipment OR annealing equipment OR HPSP) Would reveal any CHIPS Act procurement involving Korean HPSP equipment

• SEC EDGAR: supplier OR vendor AND (Korea OR KOSDAQ) AND semiconductor equipment Would identify US semiconductor companies disclosing Korean suppliers in SEC filings

• other: DART system (Korea) - HPSP company code 403870 Would verify the basic corporate claims about Korean HPSP that remain completely unverified

Significance

SIGNIFICANT — This finding represents both a methodological correction of systematic research failure and identification of the precise regulatory pathways for investigating foreign semiconductor equipment manufacturers' US touchpoints—critical for understanding CHIPS Act implementation and foreign technology integration in US semiconductor supply chains.